Develops cancer treatments for patients with solid tumors, focusing on head and neck and other squamous cell cancers.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Nov 9, 2026
−$71.2MView ↗
Competes with Merck &, Eli Lilly &, Merck KGaA, Akeso, AstraZeneca, AVEO Pharmaceuticals, BioAtla, BioNTech, Corbus Pharmaceuticals Holdings, GSK, InhibRx Biosciences, Johnson & Johnson, Merus, PDS Biotechnology, Pyxis Oncology, and Rakuten Medical
10-K for FY2025, filed Mar 30, 2026We expect to compete with currently commercially available therapies for the treatment of HNSCC, including pembrolizumab (marketed as…View ↗
Loading...